Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
abundant, adenocarcinoma, adult, advent, Affirmative, AFS, Aid, amplified, anemia, Answer, anti, Antonio, Asia, auristatin, bargaining, Belvin, Biden, Bio, BiTE, built, Campoy, carryback, CBR, chose, CJEU, colorectal, commensurate, complaint, conditionally, constitutionality, contact, deploy, destination, diffuse, dismissed, distancing, DLBCL, enrichment, enterprise, esophageal, etiology, expiry, fluid, foundation, furlough, Gilbert, Gilead, globe, gradually, Halley, hepatic, hepatocellular, histology, HNSCC, house, HR, immunotherapeutic, Importantly, imprisonment, inaccessible, incentivizing, intravenously, junction, Justice, largest, larynx, leadership, lt, malignancy, malignant, Marcia, mesothelioma, meter, migration, MMAE, Mohindru, monomethyl, motivate, mouth, multifactorial, neuropathic, nose, NSCLC, onsite, outbreak, outsourced, paclitaxel, pacmilimab, pandemic, pause, paused, placebo, plaintiff, pleural, praluzatamab, prejudice, ravtansine, readability, redirected, reevaluated, regular, remote, resume, resumption, retire, Retirement, risky, salivary, Seagen, segregation, sharp, Shield, shut, social, sooner, spider, spread, sqNSCLC, staffing, stand, straight, strongly, subtitle, subtype, supervisory, surface, surfaced, Symposium, thereunder, thought, throat, transport, tubulin, unconstrained, undevelopable, unprecedented, unspecified, vigorously, visit, Vytacera, weigh, withdrew, Wuhan, Xilio
Removed:
Accessing, acting, affinity, Akriveia, Anderson, antitumor, autoimmune, billing, BPCA, BRAF, capture, CAR, cellular, chimeric, Classical, classification, clearinghouse, conclusive, Conference, cytokine, DAKO, deliverable, delivered, discovered, dually, emerged, Ernst, evading, excessive, figure, focusing, harmonize, highest, HNSTD, Hodgkin, Humphrey, ineligible, inhibitory, Institute, introduction, irrevocably, Kadcyla, Keystone, kill, killer, leasing, ligand, MD, measurable, MEK, merkel, moiety, necessitate, nomination, nonhuman, objective, paradigm, pattern, preempted, preserving, Prime, PROCLAIM, programmed, prospectively, Rachel, reframe, remained, restore, resultant, safeguard, safeguarding, solution, subsector, suppressing, TESARO, tolerate, traded, translational, twenty, unaudited, uncouple, upregulating, vemurafenib, widen, widened, writing, xenograft, Zelboraf
Filing tables
Filing exhibits
Related press release
Associated CTMX transcripts
CTMX similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-216567 and 333-228203) and Form S-8 (Nos. 333-207694, 333-209992, 333-215795, 333-223491, 333-229916 and 333-236711) of CytomX Therapeutics, Inc. of our report dated February 24, 2021, with respect to the financial statements of CytomX Therapeutics, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2020.
/s/ Ernst & Young LLP
Redwood City, California
February 24, 2021